Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder
| Autor: | J.J. López-Ibor, J. Saiz, J. Cottraux, I. Note, R. Viñas, M. Bourgeois, M. Hernández, J.C. Gómez-Pérez |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Obsessive-Compulsive Disorder Clomipramine medicine.medical_specialty Antidepressive Agents Tricyclic Double blind Double-Blind Method Obsessive compulsive Fluoxetine Internal medicine medicine Humans Pharmacology (medical) Clinical efficacy Psychiatry Biological Psychiatry Pharmacology Response rate (survey) business.industry Clinical trial Psychiatry and Mental health Neurology Tolerability Antidepressive Agents Second-Generation Female Neurology (clinical) business Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | European Neuropsychopharmacology. 6:111-118 |
| ISSN: | 0924-977X |
| DOI: | 10.1016/0924-977x(95)00071-v |
| Popis: | There is evidence of the clinical efficacy and safety of clomipramine and the newer selective serotonin reuptake inhibitors (SSRIs) for the treatment of obsessive-compulsive disorder (OCD). In the present study, we have compared the efficacy and safety of 40 mg/day of fluoxetine and 150 mg/day of clomipramine in patients with OCD, diagnosed according to DSM-IIIR. A total of 55 patients entered this 8-week, double-blind controlled study. Efficacy for both drugs was comparable. The primary efficacy criterion, the Y-BOCS Total score, did not show any significant differences between treatment arms. Response rate was higher with clomipramine, using a 25% decrease in Y-BOCS Total score as response threshold, but there were no significant differences between treatment arms using a 35% threshold. Overall safety and tolerability were good for both drugs, being slightly better for fluoxetine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect